Laurus Labs drug firm said Thursday that its consolidated gain increased three times to ₹ 234 million rupees for the quarter of March, driven by strong sales.
The Hyderabad -based company reported a net gain of ₹ 76 million rupees for the same quarter of fiscal year 2014.
The income increased to ₹ 1,720 million rupees for the fourth quarter compared to ₹ 1,440 million rupees in the previous year, said Laurus Labs in a regulatory presentation.
For fiscal year 2000, the company said its profits increased to ₹ 358 million rupees compared to ₹ 161 million rupees in fiscal year 2023-24, he added.
The income increased to ₹ 5,554 million rupees in the last fiscal year compared to ₹ 5,041 million rupees in the financial year 2023-24.
“We deliver very good results of the fourth quarter and continue our transformative progress, reflecting a robust demand of our CDMO offers and meet Commermer’s needs,” said the founder and CEO of Laurus Labs, Satyanarayana Chava.
The company is its cooperation with the main clients, and increasing it with the promising creation of BD and capacity, he added.
“Our business remains well positioned to evolve a well diversified CMO/CDO company with a promising pipe, allowing several technological platforms and commercial excellence, thanks to the team’s commitment to the unified vision of delivering our thtial,” he said.
In the future, the company is still sure of its growth expectations, since it hopes to execute in long -date programs and new assets increasing with the income that increases in fiscal year 2015 with a continuous approach to operational excellence.
“Our capital allocation strategy is still unchanged, prioritizing investments in commercial opportunities of high value,” he added.
The company said its Board approved the second interim dividend or ₹ 0.80 per action of ₹ 2 each for financial year 2024-25.
The shares of the company traded 0.51 percent to ₹ 647.15 each in the EEB.
Posted on April 24, 2025
